Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.

Breast cancer research and treatment - 1 Nov 2011

Bayraktar Soley, Gutierrez-Barrera Angelica M, Liu Diane, Tasbas Tunc, Akar Ugur, Litton Jennifer K, Lin E, Albarracin Constance T, Meric-Bernstam Funda, Gonzalez-Angulo Ana M, Hortobagyi Gabriel N, Arun Banu K

Abstract excerpt

More than 75% of breast cancers that develop in BRCA1 mutation carriers are triple-negative breast cancers (TNBC). The aim of this study was to compare the recurrence-free survival (RFS) and overall survival (OS) in high-risk patients with TNBC with and without deleterious BRCA1/2 mutations. A to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Kaplan-Meier Estimate

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 21830012
DOI: 10.1007/s10549-011-1711-z
PMCID: PMC4334122

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21830012-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.PMID 21830012Read ↗

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.Semantic proximity Read ↗

Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.Semantic proximity Read ↗

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.Semantic proximity Read ↗

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSemantic proximity Read ↗

Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.Semantic proximity Read ↗

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.Semantic proximity Read ↗

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.Semantic proximity Read ↗

Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis.Semantic proximity Read ↗

Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.Semantic proximity Read ↗

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.Semantic proximity Read ↗

Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutationsSemantic proximity Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.